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Cyclin A1 Is Essential for Setting the Pluripotent State
and Reducing Tumorigenicity
of Induced Pluripotent Stem Cells
Samuel McLenachan,1 Cristina Mencho´n,2 Angel Raya,3–5 Antonella Consiglio,6,7 and Michael J. Edel2,8,*
The proper differentiation and threat of cancer rising from the application of induced pluripotent stem (iPS) cells
are major bottlenecks in the field and are thought to be inherently linked to the pluripotent nature of iPS cells. To
address this question, we have compared iPS cells to embryonic stem cells (ESCs), the gold standard of ground
state pluripotency, in search for proteins that may improve pluripotency of iPS cells. We have found that when
reprogramming somatic cells toward pluripotency, 1%–5% of proteins of 5 important cell functions are not set
to the correct expression levels compared to ESCs, including mainly cell cycle proteins. We have shown that
resetting cyclin A1 protein expression of early-passage iPS cells closer to the ground state pluripotent state of
mouse ESCs improves the pluripotency and reduces the threat of cancer of iPS cells. This work is a proof of
principle that reveals that setting expression of certain proteins correctly during reprogramming is essential for
achieving ESC-state pluripotency. This finding would be of immediate help to those researchers in different
fields of iPS cell work that specializes in cell cycle, apoptosis, cell adhesion, cell signaling, and cytoskeleton.
Introduction
Since the discovery of the method to reprogram fibro-blasts into induced pluripotent stem (iPS) cells 5 years ago,
it was difficult to make chimera mice, a measure of the plu-
ripotent state of the iPS cells [1], which has improved dra-
matically in a short period of time [2–4]. The term ‘‘ground
state’’ pluripotency of mouse embryonic stem cells (mESCs)
was coined by Austin Smith’s group in 2008 and refers to the
true pluripotent state of mESCs before formation of the
Epistem cells (EpiScs) [5,6]. Interestingly, insertion of KLF4, a
reprogramming factor, has been found to revert EpiScs to
ground state pluripotency, and Stat3 activation is a limiting
step for reprogramming of mouse iPS (miPS) cells toward
ground state pluripotency [7,8]. Moreover, we have found
that modifying expression of Rem2 GTPase, a suppressor of
the p53 pathway, can replace FGF2 signaling in human em-
bryonic stem cells (hESCs) and can enhance the efficiency of
reprogramming [9]. Taking this together, it suggests that iPS
cells can be modified to more closely resemble the pluripo-
tent state of ESCs, yet proteomic factors are yet to be fully
described.
Here, we investigate if modification of cyclin A1 expres-
sion levels can modify the pluripotent state of iPS cells for
a number of reasons. First, cyclin A1 has been found to be
essential for mESC survival, but not mouse fibroblasts,
suggesting a role in pluripotency [10], and second, our un-
biased antibody array screen identified cyclin A1 as over-
expressed in iPS cells compared to ESCs, the gold standard
for ground state pluripotency, suggesting that during re-
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[5,21]. mESCs and iPS cells were maintained in a G4 me-
dium, which was changed every day. The medium formu-
lation is as follows: DMEM (Gibco; # 21969-035), fetal
bovine serum (Hyclone), MEM NEAA 100 · (Gibco), peni-
cillin (10,000U/mL)/streptomycin (10,000 mg/mL) (100 · )
(Gibco; #15140-122), GlutaMAX 200mM (Gibco; #35050-
038), sodium pyruvate (Gibco; #11360), 2-Mercaptoethanol
50mM (Gibco; #31350-010) (4C), and LIF 1,000U/mL
(Chemicon; #ESG1107).
Human ESCs and iPS cells were derived and fully char-
acterized as previously published and permission attained
[22,23]. They were maintained on either human feeder
layers or on matrigel-coated plates with the HUES medium,
consisting of KO-DMEM (Invitrogen) supplemented with
10% KO-serum replacement (Invitrogen), 0.5% human al-
bumin (Grifols), 2mM Glutamax (Invitrogen), 50 mM
2-mercaptoethanol (Invitrogen), nonessential aminoacids
(Cambrex), and 10 ng/mL bFGF (Peprotech). Cultures were
maintained at 37C, 5% CO2, with medium changes every
other day. hESCs were routinely tested for normal karyo-
type. For hESC lines adapted to matrigel-coated plates, the
HUES-conditioned media from irradiated mouse embryonic
fibroblast (MEFs) were used instead. MEFs were cultured
using 10% fetal calf serum (FCS) with the DMEM. hiPS cells
were cultured the same as hESCs, and their generation has
been previously described [24,25].
Generation of iPS cells
The generation of iPS cells usingMEFs from black 6mice has
been described before [26]. For reprogramming experiments,
about 50,000 or 100,000 cells were seeded per well of a 6-well
plate and infected with retroviral supernatants of a FLAG-
tagged polycistronic retroviral vector Oct3/4, Sox2, Klf4, and
C-Myc (OSKM) in the presence of 1mg/mL polybrene. Infec-
tion consisted of a 45-min spinfection at 750 g, washed with
PBS and keratinocyte medium replaced. Two rounds of infec-
tions on consecutive days were performed. Two days after
beginning the last round of infection, cells were trypsinized
and seeded onto feeder layers of irradiated MEFs in the same
culture medium. The medium was changed upon platting to
G4 with LIF. Cultures were maintained at 37C, 5% CO2, with
medium changes every other day. iPS cells were picked, ex-
panded, and characterized for morphology, gene expression,
cell cycle, pluripotency, and teratomas [26].
Construct and virus production
cDNAs for Oct4 and Sox2 were amplified from mES RNA
by RT-PCR. Klf-4 was amplified from IMAGE clone 5111134.
c-Myc T58A mutant cDNA was amplified from DNA kindly
provided by Dr. Luciano DiCroce. The amplified cDNAs
were cloned into the EcoRI/ClaI sites of a modified
pMSCVpuro vector, which allows the expression of N-ter-
minal FLAG-tagged proteins. Retroviruses for the 4 factors
were independently produced after transfecting the cell line
Phoenix Amphotropic using the Fugene 6 reagent (Roche)
according to the manufacturer’s directions. After 24 h, the
DMEM medium was replaced, cells were incubated at 32C,
and the viral supernatant was harvested after 24 and 48 h.
Lentiviral-based cyclin A1 shRNA constructs were pur-
chased using a ps1HIV-H1 promoter backbone with a GFP
tag. Lentiviruses were produced after transfecting the 293T
cell line with packaging gag, pol and RRE, vesicular stoma-
titis virus G-protein, reverse element, and shRNA DNA us-
ing the Lipofectamine 2000 reagent according to the
manufacturer’s directions. After 24 h, the G4 medium was
replaced, cells were incubated at 37C, and the viral super-
natant was harvested at 36 h. Two hundred thousand cells
were infected with 1mL of fresh viral supernatant.
Proteomic array
Cell-signaling antibody arrays were purchased from Sig-
ma, and the manufacturer’s instructions were followed.
mESC lysates (derived from black 6 mice) were compared
to miPS cell lysates (derived from the same strain of black
6 mice). Data extracted from arrays were analyzed by the
Centre for Genomic Regulation (CRG) bio- informatics plat-
form, and differences > 1.5-fold are indicated in Fig. 1.
Immunocytochemistry, in vitro differentiation,
and AP analysis
Cells were grown on plastic coverslide chambers and fixed
with 4% paraformaldehyde (PFA). Differentiation toward
endoderm, mesoderm, and neuroectoderm was carried out
by plating embryoid body (EBs) on gelatin and the DMEM
medium, with 20% FCS changed every second day for 2–3
weeks. Cells were then stained for appropriate markers de-
scribed in the figures. Secondary antibodies used were all the
Alexa Fluor Series from Invitrogen (all 1:500). Images were
FIG. 1. Characterization of mouse embryonic stem (ES) and induced pluripotent stem (iPS) cells. (A) Top 3 sets of panels: AP
staining of C57/BL6 mouse ES cell (mESC) lines (2 lines tested, data not shown for both) and mouse iPS (miPS) cells (3F:
3 factors; 4F: 4 factors) made from MEFs of C57/BL6 mice (· 100). 4F-pool is a pool of 4 iPS clones. Cell cycle analysis by
fluorescence-activated cell sorting (FACS) for EDU (BRDU) in each clone demonstrates a high percentage of cells in the S phase
in all cases. Note that iPS cells have a higher level of cells in the G2/M phase compared to mESCs. Confocal microscopy photos
of EBs differentiating into ectoderm, endoderm, and endoderm demonstrating that mESCs can form all 3 germ layers, but some
iPS clones formed low levels of ectoderm. See Supplementary Fig. S1 for further stainings. Lower panels: Graph of real-time
polymerase chain reaction (RT-PCR) of endogenous and transgene pluripotency gene expression in ESCs and iPS cells.
Transgene expression was almost silenced in iPS cell clones. Photos of chimera mice made from mESCs (top) and miPS cells
(bottom). (B) Proteomic analyses using antibody arrays reveal differences between ES and iPS, implicating cyclin A1. Pie graph of
differences in protein expression between mESCs and miPS cells and a heat map of antibody array showing changes in protein
expression between ESCs and iPS cells. (C) Western blot validation of some of the proteins identified from the antibody array
with the greatest changes. (D) Western blot in 3 mESC lines compared to the 1 miPS cell line (4F-2 from C above) for cyclin A1
expression levels to validate lower expression levels of cyclin A1 in mESC lines. Lower panel demonstrates western blot for 3
human ESC (hESC) lines and 3 human iPS (hiPS) cell lines, showing higher levels of cyclin A1 in the hiPS cell lines. AP, alkaline
phosphatase; MEFs, mouse embryonic fibroblasts. Color images available online at www.liebertonline.com/scd
‰
2892 MCLENACHAN ET AL.
REFINING PLURIPOTENCY OF IPS CELLS 2893
taken using a Leica SP5 confocal microscope. Direct AP ac-
tivity was analyzed using an Alkaline Phosphatase Blue/
Red Membrane Substrate solution kit according to the
manufacturer’s guidelines (Sigma). Briefly, cells were wa-
shed once in cold PBS, fixed with cold 4% PFA for 1–2min,
washed with PBS once, and stained with the AP mix until
color develops (usually 5–10min).
Flow cytometry analyses
All analyses were performed on MoFlo cell sorter (Dako
Cytomation)-running Summit software. For measuring pro-
liferation, we have used the commercial kit from Invitrogen
the Click-iT EdU AlexaFluor647 Flow Cytometry Assay kit
following the manufacturer’s instructions. For the prolifera-
tion assay using the click-IT kit, instead of using the supplied
DNA dyes, we used a homemade dye 4¢,6-diamidino-2-
phenylindole (DAPI)-staining solution (0.1M Tris Base, pH
7.4; 0.9% or 150mM NaCl; 1mM CaCl2; 0.5mM MgCl2; 0.2%
bovine serum albumin; 0.1% Nonidet P40; and 10mg/mL
DAPI) 0.5mL/test (2 h/room temperature or overnight 4C).
Western blot
Western blot analyses were performed, as previously de-
scribed, using extracts of cells collected by centrifugation,
washed twice in PBS and lyzed in 1· lysis buffer [50 nM
Tris-HCl, 70mM 2-mercaptoethanol, and 1% sodium dode-
cylsulfate (SDS)], and the concentration of total protein was
measured by the Bradford assay. Lysates were then boiled
for 5min and subjected to 12% polyacrylamide SDS gel or
4%–12% SDS-resolving gel (Invitogen) electrophoresis. After
electrophoresis, proteins were transferred to a nitrocellulose
membrane using submerged transfer apparatus (BioRad),
filled with 25mM Tris Base, 200mM glycine, and 20%
methanol. After blocking with 5% nonfat dried milk in TBS-T
[50mM Tris- HCl (pH 8.0), 150mM NaCl, and 0.1% Tween
20], the membrane was incubated with the primary anti-
bodies diluted in TBS-T and washed extensively. Primary
antibodies were Cyclin A (sc596), Cyclin A2 (Epitomics
E399), Cyclin A1 (sc-15383), Cdc27 (sc13154), Actin, Cyclin
B1, Cyclin E, p16INK4a, CDK4 and Cx43 (Santa Cruz),
SMAD4 (Upstate), and ERK1/2 (Sigma M5670). The mem-
brane was washed 3 times with TBS-T and then incubated
with the appropriate horseradish peroxidase-linked second-
ary antibody (Amersham). The detection was performed
with the Western Breeze Immunodetection Kit (Invitrogen).
Real-time PCR
Total mRNA was isolated using TRIZOL, and 1mg was
used to synthesize cDNA using the Invitrogen Cloned AMV
First-Strand cDNA synthesis kit. One to 2 mL of the reaction
was used to quantify gene expression by quantitative PCR
for transgenes and endogenous pluripotent genes as previ-
ously described [27].
Soft-agar assay
Briefly, 6-well plates were coated with 1mL of a 0.4%
agar/G4 medium gel, between 25,000 and 2,500 mESCs or
iPS cells plated in a 0.3% gel placed on top. LIF was main-
tained in serum (10% FCS) in the agar gels to control growth
factor conditions. O.5mls of G4 media was changed every 3
days, and assays were left for 2–3 weeks, stained, and the
number of colonies was counted and expressed as a per-
centage of the total number of cells plated.
Chimera and teratoma assay
Chimeras were made as previously described [2–4,28].
Briefly, 11–12 black 6 iPS cells were collected and micro-
injected into blastocytes from albino mice that had a part of
its inner cell mass removed. Chimera blastocytes were then
injected back into female black 6 mice and the F1 litter ana-
lyzed. Teratomas were performed by injecting 2· 105 iPS
cells subcutaneously in both flanks of 8-week-old SCID mice.
After 3–5 weeks, tumors were removed, weighed, and pro-
cessed for histology. Apoptosis was assessed in sections of
teratomas using the tunnel assay.
Results and Discussion
Proteomic analysis reveals differences between
ESCs and iPS, implicating cyclin A1
Here, we have compared the proteomic expression dif-
ferences between mESCs and iPS cells (both derived from
C57/BL6 mice) to determine proteins important in fine
tunning pluripotency of iPS cells (using mESCs as the gold
standard). All mESC and iPS cell lines derived were from the
same strain of C57/BL6 (black 6) mice to reduce the clonal
variation, following established retroviral methods with ei-
ther 3 factors (3F; Oct4/Sox2/Klf4) or 4 factors (4F; Oct4/Sox2/
Klf4/c-Myc), and assayed at the same passage number [1]. We
analyzed 3 mES lines and 6 miPS lines, one of which was a
pool of 4 iPS clones (4F-pool). We also verified the mouse
work in 3 hESC lines, 1 fully reprogrammed human iPS (hiPS)
cell line, and 2 partially reprogrammed hiPS cell lines, making
a total of 6 ESC lines and 9 iPS cell lines studied. Character-
ization of mESC and miPS cell lines demonstrated that they
were able to differentiate into the 3 germ layers, able to form
chimera mice, stained positive for alkaline phosphatase (AP),
and expressed the main pluripotency markers, with no major
changes in the cell cycle profile (Fig. 1 and Supplementary
Fig S1; Supplementary Data are available online at www
.liebertpub.com/scd). Real-time polymerase chain reaction
(RT-PCR) for pluripotency gene expression revealed similar
expression levels between iPS cells and mESCs, and that the
retroviral transgene expression was silenced (Fig. 1).
To assess differences in protein expression, we used anti-
body arrays of the best-described proteins known to be in-
volved in 5 main cell functions: (i) cell cycle, (ii) apoptosis,
(iii) cell adhesion, (iv) cell signaling, and (v) cytoskeleton. We
found that about 82% to 89% of proteins were similarly ex-
pressed in iPS cells compared to mESCs, and that there were
between 1% and 5% differences (> 1.5-fold) in protein ex-
pression, with more differences being upregulated proteins
in iPS cells (Fig. 1). Interestingly, proteins involved in the cell
cycle control were the more frequently associated with
changes between mESCs and iPS cells, followed by proteins
controlling cell signaling and apoptosis (Fig. 1).
We found a number of protein targets already known for
having a critical role in ESC pluripotency such as
ERK, SMAD4, and cyclin A, further validating this approach
[10,11] (Fig. 1). Overall, the array data were in good
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agreement with the validation by western blot methodology,
suggesting that the array had performed well (Fig. 1).
We observed that the cdc27 protein levels were similar
between 4F-2 and 4F-3 iPS and mESCs, and lower in iPS
clones 4F-1 and 4F-4, compared to mESCs (Fig. 1C). We
found that cyclin A1, normally exclusively expressed in germ
cells only, was upregulated in iPS cells compared to mESCs,
more so than cyclin A2 (Fig. 1C). Further, 3 mESC lines tested
demonstrated a lower level of expression of cyclin A1 protein
in mESC lines (Fig. 1D). Further validation in hESCs and
hiPS cell lines by western blot demonstrated that cyclin A1 is
upregulated in 2 of the 3 iPS cell lines and slightly increased
in 1 hiPS cell compared to hESC lines (Fig. 1D).
Given this, we validated expression levels of cdc27 and
cyclin A1 in hESCs compared to hiPS and partially repro-
grammed hiPS cells that were made at the same time and
assessed at the same passage, to determine expression levels
associated with lower levels of pluripotency (partially re-
programmed hiPS). Partially reprogrammed hiPS cells were
determined based on morphology and expression of a bat-
tery of pluripotency genes (Fig. 2). We found that cyclin A1
protein levels were low in hESCs and increased in the par-
tially reprogrammed hiPS cells, which are less pluripotent
(Fig. 2). Cdc27 was expressed slightly higher in the 2 par-
tially reprogrammed hiPS cell clones in contrast to the miPS
cells (Fig. 2). Because a recent in vivo study functionally
demonstrated that cyclin A is specific for mESC survival [10],
suggesting a role for the cell cycle kinase in maintaining
pluripotency and that we had validated high levels of cyclin
A1 in partially reprogrammed hiPS, we focused on cyclin A1.
Modification of cyclin A1 protein levels resets
the pluripotent state of iPS cells
Next, we asked the question if modification of the cyclin A1
expression levels could modify the pluripotency of iPS cells
by knocking down cyclin A1 levels in iPS clones using short
hairpin RNA (shRNA) tagged with GFP (Supplementary
FIG. 2. Validation in hu-
man ESCs and iPS cells. (A)
RT-PCR of pluripotency
genes in 2 hESC lines, hiPS
cells and partially repro-
grammed iPS cells (#1 and
#2). (B) Photos of hESCs,
hiPS, and partially repro-
grammed iPS clones reveal-
ing morphological differences
with the pluripotent state.
(C) Validation by the western
blot methodology of cyclin
A1 and cdc27 in hESCs, hiPS
clones and partially repro-
grammed hiPS clones. Note
that with reduced pluripotent
potential in the partially re-
programmed iPS cells (#1 and
#2), cyclin A1 protein levels
increase compared to hESCs.
hESCs have low levels of
cyclin A1 protein expres-
sion and higher pluripotent
potential. Color images
available online at www
.liebertonline.com/scd
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Fig. S2). We have used 3 methods of analysis of plur-
ipotency, (i) RT-PCR of pluripotency gene expression, (ii) in
vitro differentiation to the 3 germ layers, and (iii) a gold
standard functional test of pluripotency, making chimera
mice. This approach is both an intensive and extensive
analysis. For treatment of cyclin A1 protein levels in ESCs
and iPS cells in Fig. 3, we chose to perform an intensive
analysis with the 3 tests of pluripotency described above.
Therefore, we tested 3 iPS cell lines for RT-PCR of plur-
ipotency gene expression. For chimera mice assays, we chose
3 pluripotent cell lines with *300 embryo transfers for each
of the conditions described in the figures (with and without
cyclin A1 shRNA treatment).
The cell cycle analysis revealed that knockdown of cyclin
A1 caused an increase in the G2/M phase with a small de-
crease in the S phase (Fig. 3). Initial analysis of 6 main
pluripotency gene expression levels did not reveal significant
differences, although a small increase was seen in Nanog
expression with knockdown of cyclin A1 (Supplementary
Fig. S2). With in vitro differentiation, a difference in the
ability to form the 3 germ layers was observed, suggesting an
effect during differentiation (data not shown). To function-
ally test this in vivo, we assessed the ability of these cells to
form chimeric mice. We found that knockdown of cyclin A1
protein levels led to an increase in the chimera rate from 42%
to 62%, suggesting a better contribution to embryo devel-
opment. Moreover, the percentage contribution to coat color
increased significantly, with 62% of pups with > 70% black
coat color, demonstrating that reduced cyclin A1 levels in
miPS gave better ability of iPS cells to contribute to the de-
velopment of the embryo (Fig. 3). We also assessed GFP-
positive cell contribution to embryo bodies at d13.5 and
FIG. 3. Modification of cyclin A1 protein levels resets the pluripotent state of iPS cells. (A)Western Blot analysis of cyclin A1
protein levels in iPS clones with stable lentiviral shRNA for cyclin A1, demonstrating 50% knockdown of protein expression.
Graph showing quantification of cyclin A1 protein levels after shRNA treatment. An FAC analysis of a cell cycle profile of
miPS cell clones compared to treated with stable lentiviral shRNA for cyclin A1. (B) Table summarizing presence of green
fluorescent protein (GFP) in gonads or the embryo body of chimera mice made from GFP iPS cells or GFP iPS cells treated
with RNAi for cyclin A1. Below are photographs of gonads (with control gonads, CG, of a GFP-OCT4 mouse) and the embryo
body at d12.5 showing GFP-cyclin A1RNAi signal. (C) A functional pluripotency assay was performed by making chimera
mice; the table summarizes the percentage of chimeras and the percent contribution to coat color of chimera mice for iPS cells
with and without cyclin A1 knockdown. A total of 331 embryo transfers were made for iPS cell lines, and 300 embryo
transfers were performed for iPS cell lines treated with cyclin A1 knockdown. Photographs showing example of chimera litter
for each condition summarized in the table. Color images available online at www.liebertonline.com/scd
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found with iPS GFP cell lines that they contributed to the
embryo body and gonads, confirming that the miPS cells
contributed to chimera formation (Fig. 3). Taken together,
these data suggest that modification of cyclin A1 protein
levels closer to that of mESCs (lower levels) can refine the
pluripotent state of iPS cells. Interestingly, knockdown of
cyclin A1 in mESCs resulted in no chimeric mice born, with
embryos dying at a very early stage of embryo development
(data not shown), supporting previous work that cyclin A is
essential for mESC survival, although that work did not
distinguish between cyclin A1 and A2 [10]. We advance that
work to show that cyclin A1 is essential for mouse embryo
development and survival. Moreover, we show from the
chimera assays that only some miPS cell lines treated with
shRNA cyclin A1 are able to proceed to the F1 generation,
suggesting further that lower levels of cyclin A1 protein ex-
pression are essential for germ-line transmission (Supple-
mentary Fig. S1).
Reducing cyclin A1 levels in high-expressing
iPS clones reduces tumorigenicity
It is thought that the oncogenic threat of iPS cells is due to
poor differentiation, determined by the pluripotent state
achieved during reprogramming. Given that we could
modify the pluripotent state of iPS by reducing cyclin A1
protein levels in iPS cells, we next asked if this could affect
the tumorigenicity of iPS cells. We used an in vitro soft-agar
assay to test anchorage-independent growth, a hallmark of
malignancy. Small colonies were able to grow slowly at an
incidence of 0.4% for ESCs and 5% for iPS cells. By reducing
cyclin A1 protein levels using stable shRNA in iPS cells, we
observed a 4-fold reduction in the tumorigenicity of miPS
cells (Fig. 2). We tested tumorigenicity from another ap-
proach using a teratoma assay in vivo. We found that re-
duction of cyclin A1 protein levels could also reduce the size
of teratomas formed by iPS significantly (Fig. 2).
FIG. 4. Reduction of cyclin A1 pro-
tein levels reduces tumorgenicity. (A)
Soft-agar tumorgenicity assay. Reduc-
tion of cyclin A1 protein levels reduces
tumorgenicity of iPS cells. Quantifica-
tion and photos of the soft-agar assay,
demonstrating that iPS cells treated
with stable lentiviral shRNA for cyclin
A1 have reduced number of colonies
forming in anchorage-independent
conditions compared to controls. Note
that the size of the mESC colony in the
photos was the smallest assessed in
the quantification. Three iPS clones
were tested. This suggests that reduc-
tion of cyclin A1 in iPS reduces
tumorigenicity. (B) In vivo tumor-
genicity assay. Graph showing differ-
ences in the size of teratomas formed
by iPS cells treated with stable lenti-
viral shRNA for cyclin A1 or controls
compared to mESCs. (C) Photographs
of teratomas formed by mESCs or iPS
cells treated with stable lentiviral
shRNA for cyclin A1 or controls
stained for Oct4 expression with DAB
compared to mESCs. Graph demon-
strates quantification of the percent of
Oct4-positive cells in teratomas. (D)
Heat maps from Agilent gene expres-
sion arrays for 3 gene groups for
mESCs and miPS cells with and
without cyclin A1 RNAi treatment
demonstrating a downregulation of
important oncogenes (Myb, Myc, and
cyclin D1) and an upregulation of
important tumor suppressor genes
(Rb) and pluripotency factors (BMP4),
explaining the reduced tumorigenicity
and increased pluripotency of iPS cells
with reduced cyclin A1. Color images
available online at www.liebertonline
.com/scd
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To understand better the mechanism of how reduced
cyclin A1 levels could be contributing to increased plur-
ipotency and reduced tumorigenicity of iPS cells, the
microarray analysis of the pluripotent cell lines with cyclin A1
knockdown reveals upregulation of cancer suppressor genes
such as Rb1 (as well as Vhl and Btg1—data not shown) with
downregulation of oncogenes Myc, Myb, and ccnd1 (Fig. 2).
Moreover, we observed a decrease in important differentia-
tion genes such as Dnmt3b, Pou3f1, and Sall1 in all 3 cell lines
with an increase in the critical pluripotency gene Bmp4 with
cyclin A1 reduction in the iPS cell lines. Taken together, these
data suggest that cyclin A1 regulates indirectly or directly a
set of genes important for tumor formation or suppression
and as well for genes regulating ground state pluripotency.
To further explain the mechanism of how knockdown of
cyclin A1 may be reducing tumorigenicity of iPS cells, we
measured apoptosis (tunnel) in mouse teratomas by IHC
(Fig. 4). We found that with iPS cells, a significant increase in
apoptosis occurs with cyclin A1 knockdown (Supplementary
Fig. S2). These results highlight that an increase in apoptosis
as a result of cyclin A1 knockdown could explain the re-
duction of tumor growth in vivo. It has been previously
shown that high c-Myc levels associated with lower cyclin A1
levels under growth factor-reduced conditions cause apo-
ptosis [12,13].
Given we had seen a reduction in tumorigenicity (both in
vitro and in vivo measures) and better pluripotency of iPS
with reduction of cyclin A1 protein levels in iPS cells, we
thought that it could be a result of better differentiation of
the cells. For iPS cells, we found that the number of Oct4-
positive cells still present after 3 weeks of differentiation
in vivo was reduced with knockdown of cyclin A1 protein
levels (Fig. 2). These data suggest that the better differenti-
ation of iPS cells with cyclin A1 knockdown may also con-
tribute to the reduction of tumorigenicity of the iPS cells.
In conclusion, the data demonstrate that during repro-
gramming, achieving the correct expression levels of 1%–5%
of proteins is essential to achieve closer to ground state
pluripotency. We have shown that modifying cyclin A1
protein levels in iPS cells can increase pluripotency and re-
duce tumorigenicity of iPS cells. Recently, it has been shown
that a number of cell cycle genes such as p27KIP, Cyclin D1,
and p53 function play an important role in maintaining and
attaining pluripotency of hESCs and iPS cells; however, a
direct link of the cell cycle to the pluripotency program is yet
to be established [9,14–20]. We expect that not all iPS cell
lines would have overexpressed cyclin A1, and for those iPS
clones, that would be good news. However, this work goes
further; it is a proof of principle that setting certain protein
expression correctly is essential for reaching ground state
pluripotency equal to ESCs. This finding is of immediate help
to those researchers in different fields of iPS that specialize in
cell cycle, apoptosis, cell adhesion, cell signaling, and cyto-
skeleton.
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